Glenmark Pharmaceuticals Announces Q2 FY27 Results and Key Governance Decisions

Glenmark Pharmaceuticals Announces Q2 FY27 Results and Key Governance Decisions​

Glenmark Pharmaceuticals Limited, during a board meeting held on July 31, 2026, approved the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The board also made several key governance decisions, including reconstituting the Risk Management Committee and approving updates to core company policies.

The meeting saw the approval of the financial results, which were subjected to a limited review by statutory auditors. Additionally, the board ratified amendments to five major company policies: Policy on Related Party Transactions and its Materiality, Policy on Determination of Materiality for Disclosures, Insider Trading Policy, Dividend Distribution Policy, and Nomination and Remuneration Policy.

Financial Performance Snapshot (Q ended June 30, 2026)​

The company reported both Standalone and Consolidated results for the quarter in millions of Indian Rupees. The Q2 data shows significant performance metrics across various income and expense lines.

A summary of the key financial highlights for the standalone segment compared to previous periods is presented below:


The consolidated financial results provide a broader view of the group’s performance:

Governance and Committee Reconstitution​

The Board approved the reconstitution of the Risk Management Committee, effective August 01, 2026. Ms. Patricia Andrews was appointed as the Chairperson, while Mr. Glenn Saldanha, Mr. Anurag Mantri, and Mr. Dipankar Bhattacharjee were designated as Members of the committee.

Operational Highlights​

The board meeting addressed several material operational events and financial provisions:

• Asset Transfer: The transfer of the Company's Nebulizer brands and intellectual property portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary, was approved for a cash consideration of Rs. 2,230 million.
• Litigation Settlement Provisions: For the quarter ended March 31, 2026, the Company accounted for significant expenses related to litigation. This included a provision for an estimated settlement amount of Rs. 3,232.32 and Rs. 2,780.70 in relation to a settlement with a putative direct purchaser class and the state attorney general in Pennsylvania. Additionally, a commercial settlement amounting to Rs 976 million was accounted for concerning United Healthcare Services, Inc.
• Expense Analysis: The standalone results highlighted substantial expenses related to inventory provision (Rs. 5,901 million), changes in receivables and other current assets (Rs. 4,958.32 million), impairment of property, plant and equipment (Rs. 2,278.91 million), and legal costs associated with the litigation matters (Rs. 1,394.68 million).
• Labour Code Impact: The Group recognized the financial implications of the Government of India's consolidated labor legislations, recognizing Rs. 1,138.91 in the consolidated financial results and Rs. 1,130.73 in the standalone financial results toward employee benefits.

General Meeting Details​

The company's 48th Annual General Meeting (AGM) of members is scheduled for Friday, September 11, 2026, at 2:00 P.M., which will be held via video-conferencing or other audiovisual means. The record date for determining dividend entitlement for the Financial Year ended March 31, 2026, has been set as Monday, August 31, 2026.

GLENMARK Stock Price Movement​

Glenmark Pharmaceuticals Limited shares climbed today, closing at ₹2233.90 after gaining 2.73% in the market. The stock settled amidst robust trading activity, with a volume totaling 371,153 shares throughout the session.